Methods for the treatment of back pain

• US 20060009478A1
• Filed: 03/23/2005
• Published: 01/12/2006
• Est. Priority Date: 10/15/2003
• Status: Abandoned Application

• Current Assignee: Grant L. Schoenhard, Nadav Friedmann, Remi Barbier
• Original Assignee: Grant L. Schoenhard, Nadav Friedmann, Remi Barbier
• Inventors: Barbier, Remi, Schoenhard, Grant L., Friedmann, Nadav
• Application Number:
  US11/089,283
• Publication Number:
  US 20060009478A1
• Time in Patent Office: Days
• US Class Current: 514/282
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Methods and materials, including novel compositions, dosage forms and methods of administration, useful for treating back pain using opioid antagonists, including combinations of opioid antagonists and opioid agonists. Methods and materials comprising opioid antagonists or combinations opioid antagonists and agonists may optionally include one or more additional therapeutic agents.

Claims

1. A method for treating back pain in a human subject comprising administering to the subject an opioid agonist and an opioid antagonist, wherein back pain is alleviated and wherein the amount of the antagonist is effective to attenuate withdrawal.

2. The method of claim 1, wherein the incidence, severity or duration of withdrawal is attenuated.

3. The method of claim 1, wherein one or more symptoms or signs of withdrawal are attenuated.

4. The method of claim 3, wherein the symptom or sign of withdrawal is feeling sick, stomach cramps, muscle spasms/twitching, a feeling of coldness, heart pounding, muscular tension, aches and pains, yawning, funny eyes, or insomnia/problems sleeping.

5. The method of claim 3, wherein the symptom or sign of withdrawal is hyperalgesia, increased heart rate, increased respiratory rate, increased pupilary diameter, muscle cramps, yawning, upset stomach, runny nose, watery eyes, abdominal cramps, clammy/damp skin, or chills/gooseflesh.

6. The method of claim 1, wherein the withdrawal is measured on the Short Opiate Withdrawal Scale (SOWS).

8. The method of claim 1, wherein the incidence, severity or duration of one or more of the opioid-related adverse effects is attenuated.

18. The method of claim 1, 7 or 10, wherein the back pain is associated with a neck, upper back, middle back or lower back of the subject.

19. The method of claim 1, 7 or 10, wherein the back pain is chronic.

20. The method of claim 1, 7 or 10, wherein the back pain is moderate or severe.

21. The method of claim 1, 7 or 10, wherein the back pain is low back pain.

22. The method of claim 1, 7 or 10, wherein the pain is measured as pain intensity.

23. The method of claim 22, wherein the pain intensity is measured as percent change from a baseline measurement of the subject.

24. The method of claim 23, wherein the pain intensity is reduced from the baseline measurement.

25. The method of claim 1, 7 or 10, wherein the pain is measured on an 11-point numerical scale.

26. The method of claim 25, wherein the pain is reduced in points, as compared to a baseline measurement of the subject.

27. The method of claim 25, wherein the pain is reduced by at least 1 point, as compared to a baseline measurement of the subject.

28. The method of claim 1, 7 or 10 further comprising administering to the subject an additional therapeutic agent that is a non-steroidal anti-inflammatory drug, muscle relaxant, cytokine inhibitor, corticosteroid, anti-rheumatic drug, anticonvulsant agent, tricyclic antidepressant agent, anti-dynorphin agent, or glutamate receptor antagonist agent.

29. The method of claim 28, wherein the additional therapeutic agent is a TNF-α

inhibitor, corticosteroid, anti-rheumatic drug, non-steroidal anti-inflammatory drug, celecoxib, ropecoxib, valdecoxib, etanercept, infiximab, anti-TNF-α

, D2E7 human Mab, CDP-870, CDP-571, humicade, PEGylated soluble TNF-α

Receptor-1, TBP-1, PASSTNF-alpha, AGT-1, ienercept, CytoTAB, TACE, small molecule TNF mRNA synthesis inhibitor, PEGylated p75TNFR Fc mutein (Immunex), TNF-α

antisense inhibitor, methotrexate, leflunomide, D-Penicillamine, sulfasalazine, a gold composition, minocycline, azathioprine, hydroxychloroquine, an antimalarial drug, cyclosporine, or a biologic agent that designed to either inhibit or supplement a cytokine.

30. The method of claims 1, 7 or 10, wherein the antagonist, the agonist, or both the antagonist and the agonist is administered chronically.

31. The method of claims 1, 7 or 10, wherein the antagonist, the agonist, or both the antagonist and the agonist is administered for at least six weeks.

32. The method of claims 1, 7 or 10, wherein the antagonist, the agonist, or both the antagonist and the agonist is administered for at least twelve weeks.

33. The method of claim 1, 7 or 10 wherein the subject is physically dependent on the same or a different opioid agonist prior to administration of the administration of the opioid antagonist.

34. The method of claim 1, 7 or 10 wherein the subject is tolerant to an opioid agonist prior to administration of the administration of the opioid antagonist.

35. The method of claim 1, 7 or 10 wherein the subject is addicted to an opioid agonist prior to administration of the administration of the opioid antagonist.

36. The method of claim 1, 7 or 10 wherein the amount of the opioid antagonist is 0.002 mg, less than 0.002 mg, about 0.001 mg, less than 0.001 mg, more than 0.0001 mg, about 0.0001 mg, 0.00001 mg, less than 0.00001 mg, more than 0.00001 mg, about 0.000001 mg, less than 0.000001 mg, or more than 0.000001 mg.

37. The method of claim 36, wherein the agonist, the antagonist, or both the agonist and the antagonist is administered twice a day.

38. The method of claims 36, wherein the agonist, the antagonist, or both the agonist and the antagonist is administered once a day.

39. The method of claim 1, 7 or 10, wherein the agonist, the antagonist, or both the agonist and the antagonist is administered no more than twice in a 24-hour period.

40. The method of claims 1, 7 or 10, wherein the agonist, the antagonist, or both the agonist and the antagonist is administered no more than once in a 24-hour period.

41. The method of claims 1, 7 or 10, wherein the amount of the antagonist is 0.004 mg or less in a 24-hour period.

42. The method of claims 1, 7 or 10, wherein the amount of the antagonist is 0.002 mg or less in a 24-hour period.

43. The method of claims 1, 7 or 10, wherein the antagonist, the agonist, or both the antagonist and the agonist is administered in an oral dosage form.

44. The method of claim 43, wherein the oral dosage form is a solid oral dosage form or a liquid oral dosage form.

45. The method of claims 1, 7 or 10, wherein the agonist is codeine, hydromorphone, meperidine, morphine, oxycodone, oxymorphone, propoxyphene, hydrocodone, pentazocine, fentanyl, sufentanyl, methadone, tramadol, or dihydrocodeine.

46. The method of claims 1, 7 or 10, wherein the antagonist is naltrexone, nalmefene, or naloxone.

47. The method of claims 1, 7 or 10, wherein the mode of administration of the agonist, the antagonist, or both, is oral, intravenous, intrathecal, epidural, intramuscular, subcutaneous, perineural, intradermal, topical, or transcutaneous.

48. The method of claims 1, 7 or 10, wherein the agonist is oxycodone and the antagonist is naltrexone.

49. The method of claims 1, 7 or 10, wherein the amount of the agonist is from about 2.5 mg to about 160 mg.

50. The method of claims 1, 7 or 10, wherein the amount of the antagonist is from about 0.0001 mg to about 0.004 mg.

51. The method of claims 1, 7 or 10, wherein the amount 6f the agonist is about 2.5 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 80 mg, about 160 mg, or about 320 mg.

52. The method of claims 1, 7 or 10, wherein the amount of the antagonist administered is at least about 1250 fold less than the amount of the agonist administered.

53. The method of claims 1, 7 or 10, wherein the amount of the antagonist administered is at most about 1,600,000 fold less than the amount of the agonist administered.

54. The method of claim 1, 7 or 10, wherein the amount of the opioid antagonist administered to the subject is no more than about 80.4 μ

gs, about 40.2 μ

gs, about 20 μ

gs, about 10 μ

gs, about 5 μ

gs, about 2.5 μ

gs, about 1.2 μ

gs, about 0.6 μ

g about 0.3 μ

g or about 0.12 μ

g.

55. The method of claim 1, 7 or 10, wherein the amount of the opioid antagonist administered to the subject is at least about 0.0002 μ

g about 0.1 μ

g about 0.2 μ

g about 0.4 μ

g about 0.8 μ

g about 1.6 μ

g about 3.3 μ

g or about 6.6 μ

g of the opioid antagonist.

56. The method of claim 1, 7 or 10, wherein the amount of the antagonist administered is effective to enhance the potency of the agonist for alleviating back pain.

57. The method of claim 56, wherein the enhanced potency is measured by administering a lower dose to achieve alleviation of back pain.

7. A method for treating back pain in a human subject comprising administering to the subject an opioid agonist and an opioid antagonist, wherein back pain is alleviated and wherein the amount of the antagonist is effective to attenuate one or more opioid-related adverse effects.

9. The method of claim 7, wherein the adverse effect is constipation, somnolence, or pruritus.

10. A method for treating back pain in a human subject comprising administering to the subject an opioid agonist and an opioid antagonist, wherein back pain is alleviated and wherein the amount of the antagonist is effective to attenuate one or more adverse effects of dependence, tolerance, or addiction.

11. The method of claim 10, wherein the incidence, severity or duration of the adverse effect is attenuated.

12. The method of claim 10, wherein the adverse effect is dependence, and one or more symptoms or signs of dependence is attenuated.

13. The method of claim 12, wherein the symptom or sign of dependence is anxiety, irritability, hot flashes, joint pain, salivation, lacrimation, rhinorrhea, diaphoresis, piloerection, nausea, vomiting, abdominal cramps, diarrhea, or sleep disturbances/insomnia.

14. The method of claim 10, wherein the adverse effect is tolerance, and one or more symptoms or signs of tolerance is attenuated.

15. The method of claim 14, wherein the symptom or sign of tolerance is a need to increase dose to maintain pain relief, a decrease in duration of pain relief for a given dose, anxiety, or sweating.

16. The method of claim 10, wherein the adverse effect is addiction, and one or more symptoms or signs of addiction is attenuated.

17. The method of claim 10, wherein the symptom or sign of addition is impaired control over opioid agonist, compulsive use of opioid agonist, continued use of opioid agonist despite harm to the subject, or craving of opioid agonist.

58. A method for treating back pain in a human subject being administered an opioid agonist, the method comprising administering to the subject an opioid antagonist, wherein back pain is alleviated, and wherein the amount of the antagonist is effective to attenuate withdrawal.

61. The method of claims 58, 59 or 60, wherein the subject is physically dependent on an opioid agonist prior to administration of the administration of the opioid antagonist.

62. The method of claims 58, 59 or 60, wherein the subject is tolerant to an opioid agonist prior to administration of the administration of the opioid antagonist.

63. The method of claims 58, 59 or 60, wherein the subject is addicted to an opioid agonist prior to administration of the administration of the opioid antagonist.

59. A method for treating back pain in a human subject being administered an opioid agonist, the method comprising administering to the subject an opioid antagonist, wherein back pain is alleviated, and wherein the amount of the antagonist is effective to attenuate one or more opioid-related adverse effects.

60. A method for treating back pain in a human subject being administered an opioid agonist, the method comprising administering to the subject an opioid antagonist, wherein back pain is alleviated, and wherein the amount of the antagonist is effective to attenuate one or more adverse effects of dependence, tolerance, or addiction.

64. A method of dosing an opioid antagonist administered to a human subject having back pain, the method comprising the steps of:

(a) administering an amount of an opioid antagonist and an amount of an opioid agonist to the subject;

(b) assessing back pain;

(c) measuring a level of the opioid antagonist or a surrogate of the opioid antagonist in a sample from the subject; and

(d) adjusting the amount of the opioid antagonist or the amount of the opioid agonist to the subject based on the measured level.

65. The method of claim 64, wherein step (d) comprises adjusting the amount of the opioid antagonist administered to the subject.

66. The method of claim 64, wherein step (d) comprises adjusting the amount of the opioid agonist administered to the subject.

67. The method of claim 64, wherein the amount of the opioid antagonist administered to the subject is increased if the measured level is lower than a predetermined value.

68. The method of claim 64, wherein the amount of the opioid antagonist administered to the subject is decreased in the measured level is higher than a predetermined value.

69. The method of claim 64, wherein the amount of the opioid antagonist administered to the subject is maintained in the measured level is within a predetermined range.

70. The method of claim 64, further comprising the step of increasing the amount of the opioid agonist administered to the subject.

71. The method of claim 64, wherein the level of 6β

-naltrexol is measured as a surrogate.

72. The method of claim 64, wherein the 6β

-naltrexol is a surrogate marker for assessing one or more symptoms or signs of an arthritic condition, inflammation associated with a chronic condition, or chronic pain.

73. The method of claim 64, wherein the sample is a plasma sample.

74. A method of dosing an opioid antagonist to a human subject having back pain, the method comprising the steps of:

(a) administering an amount of an opioid antagonist and an amount of an opioid agonist to the subject;

(b) assessing back pain; and

(c) adjusting the amount of the opioid antagonist administered to the subject the back pain is not alleviated to a desired extent.

75. The method of claim 74, wherein step (a) comprises repeatedly administering the opioid antagonist such that a steady state is achieved.

76. The method of claim 74, wherein step (c) also comprises maintaining the amount of the opioid agonist administered to the subject.

77. The method of claim 74, further comprising the steps of:

(d) re-assessing the back pain after step (c);

(e) adjusting the amount of the opioid agonist if the back pain is not alleviated to a desired extent.

78. The method of claim 74, wherein the back pain is low back pain.

79. The method of claim 78, wherein the back pain is measured as pain intensity.

80. The method of claim 79, wherein the pain intensity measurement is attenuated as compared to a pain intensity baseline measurement of the subject.

81. The method of claim 79, wherein the pain intensity measurement is reduced by at least about 20%, at least about 50%, or at least about 90% compared to a pain intensity baseline measurement of the subject.

82. The method of claim 74, further comprising the steps of:

(d) measuring a level of the opioid antagonist or a surrogate of the opioid antagonist in a sample from the subject, and

(e) further adjusting the amount of the opioid antagonist based on the measured level of the antagonist or the surrogate.

83. The method of claim 74, wherein the sample is a plasma sample.

84. A method of dosing an opioid antagonist to a human subject, the method comprising the steps of:

(a) administering an amount of an opioid antagonist and an amount of an opioid agonist to the subject;

(b) measuring a level of the opioid antagonist or a surrogate of the opioid antagonist in a sample from the subject; and

(c) adjusting the amount of the opioid antagonist administered to the subject if the measured level is outside a predetermined range.

85. The method of claim 84, further comprising repeating step (a) if the measured level is within the predetermined range.

86. The method of claim 85, wherein the sample is a plasma sample.

87. The method of claim 86, wherein the predetermined range is a range of plasma concentrations predicted by a model of plasma concentration-effect relationship as the range which provides about 20% or greater reduction in pain intensity, or about 50% or greater reduction in pain intensity, or about 90% or greater reduction in pain intensity.

88. The method of claim 87, wherein the predetermined plasma concentration is based on the plasma concentration-effect relationship shown in FIG. 11 or the plasma concentration-effect relationship shown in FIG. 12.

89. A method of determining the amount of an opioid antagonist or opioid agonist to be administered to a human subject having back pain, the method comprising the steps of:

(a) assessing back pain in a human subject being administered an opioid antagonist and an opioid agonist;

(b) measuring a level of the opioid antagonist or a surrogate of the opioid antagonist in a sample obtained from the human subject;

(c) on the basis of the measured level, adjusting the amount of the opioid antagonist or the amount of the opioid agonist for administration to the human subject.

90. The method of claim 89, wherein the amount of the opioid antagonist administered to the subject is increased if the measured level is lower than a predetermined value.

91. The method of claim 89, wherein the amount of the opioid antagonist administered to the subject is decreased in the measured level is higher than a predetermined value.

92. The method of claim 89, wherein the amount of the opioid antagonist administered to the subject is maintained in the measured level is within a predetermined range.

93. A method of reducing the level of a biomarker in a human subject having back pain, comprising administering to the subject a composition comprising an opioid antagonist and optionally an opioid agonist.

94. The method of claim 93, further comprising administering an opioid agonist to the subject.

95. The method of claim 93, wherein the biomarker is a cytokine.

96. The method of claim 93, wherein the biomarker is IL1a, IL1b, IL2, IL4, IL5, IL6, IL13, GM-CSF, interferon-γ

, or TNFα

.

97. The method of claim 93, wherein the biomarker is TNFα

, IL6, or IL4.

98. The method of claim 93, wherein the biomarker is TNFα

, and the level is reduced to about 0.2 ng/ml or lower.

99. The method of claim 93, wherein the biomarker is IL6, and the level is reduced to about 0.18 ng/ml or lower.

100. The method of claim 93, wherein the biomarker is IL4, and the level is reduced to about 0.23 ng/ml or lower.

101. A method to monitor the response of a human subject being treated for back pain, by administering an opioid antagonist, comprising the steps of:

(a) determining the level of one or more one biomarker(s) in a first sample from the subject prior to treatment with the opioid antagonist;

(b) determining the level of the biomarker in at least a second sample from the subject subsequent to the initial treatment with the opioid antagonist; and

(c) comparing the level of the biomarker in the second sample with the level of the biomarker in the first sample;

wherein a change in the level of the biomarker in the second sample compared to the level of the biomarker in the first sample indicates the effectiveness of the treatment.

103. The method of claims 101 or 102, further comprising the step of adjusting the amount of the opioid antagonist administered to the subject after comparing the levels of the biomarker.

104. The method of claim 103, further comprising the step of adjusting the amount of the opioid agonist administered to the subject after comparing the levels of the biomarker.

105. The method of claims 101 or 102, wherein the biomarker is a cytokine.

106. The method of claims 101 or 102, wherein the biomarker is IL1a, IL1b, IL2, IL4, IL5, IL6, IL13, GM-CSF, interferon-γ

, or TNFα

.

107. The method of claims 101 or 102, wherein the biomarker is TNFα

, IL6, or IL4.

108. The method of claims 101 or 102, wherein the biomarker is TNFα

, and the level is reduced to about 0.2 ng/ml or lower.

109. The method of claims 101 or 102, wherein the biomarker is IL6, and the level is reduced to about 0.18 ng/ml or lower.

110. The method of claims 101 or 102, wherein the biomarker is IL4, and the level is reduced to about 0.23 ng/ml or lower.

102. A method to monitor the response of a human subject being treated for back pain, by administering an opioid antagonist and an opioid agonist, comprising the steps of:

(a) determining the level of one or more one biomarker(s) in a first sample from the subject prior to treatment with the opioid antagonist and the opioid agonist;

(b) determining the level of the biomarker in at least a second sample from the subject subsequent to the initial treatment with the opioid antagonist and the opioid agonist; and

(c) comparing the level of the biomarker in the second sample with the level of the biomarker in the first sample;

wherein a change in the level of the biomarker in the second sample compared to the level of the biomarker in the first sample indicates the effectiveness of the treatment.